BACKGROUND: Youth with type 1 diabetes (T1D) are at risk for weight gain due to the epidemic of childhood overweight/obesity and common use of intensive insulin therapy; the latter resulted in weight gain in the Diabetes Control and Complications Trial. OBJECTIVE: To assess overweight/obesity prevalence and intensive insulin therapy use in youth with T1D over a decade and identify factors associated with weight status and glycemic control. METHODS: We obtained cross-sectional data from four unique cohorts (1999, 2002, 2006, and 2009). Youth (N = 507, 49% male) were 8-16 yr old with T1D duration ≥6 months, A1c 6.0-12.0% (42-108 mmol/mol), and daily insulin dose ≥0.5 U/kg. RESULTS: Across cohorts, age, body mass index (BMI) percentile, and A1c ranged from 12.0 ± 2.2 to 12.8 ± 2.3 yr, 70 ± 22 to 72 ± 21, and 8.3 ± 1.0 (67 ± 11) to 8.5 ± 1.1% (69 ± 12 mmol/mol), respectively. Intensive insulin therapy use increased from 52 to 97% (p < 0.001) between 1999 and 2009. However, prevalence of overweight/obesity remained similar, 27% (1999), 36% (2002), 33% (2006), and 31% (2009) (p = 0.54), as did z-BMI. In multivariate analysis, higher A1c was related to higher insulin dose (p < 0.01), less frequent blood glucose monitoring (p < 0.001), and non-white race (p < 0.001); A1c was not related to z-BMI, intensive insulin therapy, or cohort. z-BMI was related to insulin dose (p < 0.005) but not intensive insulin therapy or cohort. CONCLUSIONS: Despite near-universal implementation of intensive insulin therapy, overweight/obesity prevalence in youth with T1D remained stable over a decade, similar to the general pediatric population. However, A1c remained suboptimal, underscoring the need to optimize T1D treatment to reduce future complication risk.
BACKGROUND: Youth with type 1 diabetes (T1D) are at risk for weight gain due to the epidemic of childhood overweight/obesity and common use of intensive insulin therapy; the latter resulted in weight gain in the Diabetes Control and Complications Trial. OBJECTIVE: To assess overweight/obesity prevalence and intensive insulin therapy use in youth with T1D over a decade and identify factors associated with weight status and glycemic control. METHODS: We obtained cross-sectional data from four unique cohorts (1999, 2002, 2006, and 2009). Youth (N = 507, 49% male) were 8-16 yr old with T1D duration ≥6 months, A1c 6.0-12.0% (42-108 mmol/mol), and daily insulin dose ≥0.5 U/kg. RESULTS: Across cohorts, age, body mass index (BMI) percentile, and A1c ranged from 12.0 ± 2.2 to 12.8 ± 2.3 yr, 70 ± 22 to 72 ± 21, and 8.3 ± 1.0 (67 ± 11) to 8.5 ± 1.1% (69 ± 12 mmol/mol), respectively. Intensive insulin therapy use increased from 52 to 97% (p < 0.001) between 1999 and 2009. However, prevalence of overweight/obesity remained similar, 27% (1999), 36% (2002), 33% (2006), and 31% (2009) (p = 0.54), as did z-BMI. In multivariate analysis, higher A1c was related to higher insulin dose (p < 0.01), less frequent blood glucose monitoring (p < 0.001), and non-white race (p < 0.001); A1c was not related to z-BMI, intensive insulin therapy, or cohort. z-BMI was related to insulin dose (p < 0.005) but not intensive insulin therapy or cohort. CONCLUSIONS: Despite near-universal implementation of intensive insulin therapy, overweight/obesity prevalence in youth with T1D remained stable over a decade, similar to the general pediatric population. However, A1c remained suboptimal, underscoring the need to optimize T1D treatment to reduce future complication risk.
Authors: Reinhard W Holl; Peter G F Swift; Henrik B Mortensen; Helle Lynggaard; Phillip Hougaard; Henk-Jan Aanstoot; Francesco Chiarelli; Denis Daneman; Thomas Danne; Harry Dorchy; Patrick Garandeau; Steven Greene; Hilary M C V Hoey; Eero A Kaprio; Mirjana Kocova; Pedro Martul; Nobuo Matsuura; Kenneth J Robertson; Eugen J Schoenle; Oddmund Sovik; Rosa-Maria Tsou; Maurizio Vanelli; Jan Aman Journal: Eur J Pediatr Date: 2002-11-26 Impact factor: 3.183
Authors: Maria J Redondo; Crystal G Connor; Katrina J Ruedy; Roy W Beck; Craig Kollman; Jamie R Wood; Bruce Buckingham; Georgeanna J Klingensmith; Janet Silverstein; William V Tamborlane Journal: Pediatr Diabetes Date: 2013-07-24 Impact factor: 4.866
Authors: Ravi Retnakaran; Jackie Hochman; J Hans DeVries; Helene Hanaire-Broutin; Robert J Heine; Vincent Melki; Bernard Zinman Journal: Diabetes Care Date: 2004-11 Impact factor: 19.112
Authors: Nuala P Murphy; Suzanne M Keane; Ken K Ong; Martha Ford-Adams; Julie A Edge; Carlo L Acerini; David B Dunger Journal: Diabetes Care Date: 2003-03 Impact factor: 19.112
Authors: Ingrid M Libman; Massimo Pietropaolo; Silva A Arslanian; Ronald E LaPorte; Dorothy J Becker Journal: Diabetes Care Date: 2003-10 Impact factor: 19.112
Authors: Karl E Minges; Robin Whittemore; Stuart A Weinzimer; Melinda L Irwin; Nancy S Redeker; Margaret Grey Journal: Diabetes Res Clin Pract Date: 2017-02-04 Impact factor: 5.602
Authors: Dean P Hainsworth; Ionut Bebu; Lloyd P Aiello; William Sivitz; Rose Gubitosi-Klug; John Malone; Neil H White; Ronald Danis; Amisha Wallia; Xiaoyu Gao; Andrew J Barkmeier; Arup Das; Shriji Patel; Thomas W Gardner; John M Lachin Journal: Diabetes Care Date: 2019-03-04 Impact factor: 19.112
Authors: Petter Bjornstad; Julie A Lovshin; Yuliya Lytvyn; Genevieve Boulet; Leif E Lovblom; Omar N Alhuzaim; Mohammed A Farooqi; Vesta Lai; Josephine Tse; Leslie Cham; Andrej Orszag; Daniel Scarr; Alanna Weisman; Hillary A Keenan; Michael H Brent; Narinder Paul; Vera Bril; Bruce A Perkins; David Z I Cherney Journal: Diabetes Care Date: 2018-02-02 Impact factor: 19.112
Authors: Nuria Vilarrasa; Miguel Angel Rubio; Inka Miñambres; Lillian Flores; Assumpta Caixàs; Andrea Ciudin; Marta Bueno; Pedro Pablo García-Luna; María D Ballesteros-Pomar; Marisol Ruiz-Adana; Albert Lecube Journal: Obes Surg Date: 2017-04 Impact factor: 4.129
Authors: Karl E Minges; Robin Whittemore; Ariana M Chao; Vanessa Jefferson; Kathryn M Murphy; Margaret Grey Journal: Diabetes Educ Date: 2016-06-13 Impact factor: 2.140